Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Shares Outstanding (2016 - 2024)

Historic Shares Outstanding for Spyre Therapeutics (SYRE) over the last 10 years, with Q3 2024 value amounting to $51.4 million.

  • Spyre Therapeutics' Shares Outstanding rose 116935.05% to $51.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $51.4 million, marking a year-over-year increase of 116935.05%. This contributed to the annual value of $36.1 million for FY2023, which is 127938.03% up from last year.
  • As of Q3 2024, Spyre Therapeutics' Shares Outstanding stood at $51.4 million, which was up 116935.05% from $50.8 million recorded in Q2 2024.
  • Over the past 5 years, Spyre Therapeutics' Shares Outstanding peaked at $51.4 million during Q3 2024, and registered a low of $2.0 million during Q4 2021.
  • For the 5-year period, Spyre Therapeutics' Shares Outstanding averaged around $26.8 million, with its median value being $36.1 million (2023).
  • As far as peak fluctuations go, Spyre Therapeutics' Shares Outstanding crashed by 9596.7% in 2022, and later skyrocketed by 146737.65% in 2024.
  • Spyre Therapeutics' Shares Outstanding (Quarter) stood at $48.0 million in 2020, then plummeted by 95.88% to $2.0 million in 2021, then surged by 32.42% to $2.6 million in 2022, then surged by 1279.38% to $36.1 million in 2023, then skyrocketed by 42.54% to $51.4 million in 2024.
  • Its Shares Outstanding was $51.4 million in Q3 2024, compared to $50.8 million in Q2 2024 and $36.6 million in Q1 2024.